Client News

Home/Client News
Client News 2018-08-28T11:24:45+00:00
January 29, 2018
Rexahn Pharmaceuticals Receives Notice of Allowance for A New U.S. Patent Covering the Use of RX-5902 (Supinoxin™)
ROCKVILLE, Md., Jan. 29, 2018 (GLOBE NEWSWIRE) -- Rexahn Pharmaceuticals, Inc. (NYSE American:RNN), a clinical stage biopharmaceutical company developing innovative, targeted therapeutics for the treatment ...
January 29, 2018
Data Highlighting Advaxis’ Antigen Delivery Platform Accepted for Multiple Presentations at 2018 Keystone Symposia Conference on Cancer Immunotherapies
PRINCETON , N.J.--(BUSINESS WIRE)--Advaxis, Inc. (ADXS), a late-stage biotechnology company focused on the discovery, development and commercialization of immunotherapy products, announces that three abstracts highlighting the ...
January 29, 2018
Bellerophon Therapeutics Announces Enrollment Exceeds 100 Patients in Phase 3 INOvation-1 Study Evaluating INOpulse® for Treatment of Pulmonary Arterial Hypertension
WARREN, N.J., Jan. 29, 2018 (GLOBE NEWSWIRE) -- Bellerophon Therapeutics, Inc. (BLPH), a clinical-stage biotherapeutics company, today announced that enrollment in its Phase 3 INOvation-1 study ...
January 26, 2018
Prometic to host Key Opinion Leader meeting on novel treatments for idiopathic pulmonary fibrosis (IPF)
LAVAL, QC , Jan. 25, 2018 /CNW/ - Prometic Life Sciences Inc. (PLI.TO) (PFSCF)("Prometic") announced  that it will host a Key Opinion Leader (KOL) meeting on ...
January 26, 2018
Onxeo Receives EPO Intent-to-Grant Notice for Key AsiDNA™ Patent, Extending IP Protection in Europe Until 2031
PARIS--(BUSINESS WIRE)--Regulatory News: Onxeo S.A. (Euronext Paris, NASDAQ Copenhagen: ONXEO - FR0010095596), (“Onxeo” or the “Company”), a biotechnology company specializing in the development of innovative drugs ...
January 26, 2018
ESSA Announces Management Team Change
HOUSTON and VANCOUVER , Jan. 25, 2018 /CNW/ - ESSA Pharma Inc. (TSXV: EPI; Nasdaq: EPIX) ("ESSA" or the "Company") announced today that  Frank Perabo, ...
January 26, 2018
Santhera Receives Negative CHMP Opinion on Appeal for Authorization of Raxone® in Duchenne Muscular Dystrophy
Liestal, Switzerland, January 26, 2018 - Santhera Pharmaceuticals (SIX: SANN) announces that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) ...
January 26, 2018
ESSA to Present at Noble Capital Markets' NobleCon14
HOUSTON and VANCOUVER, Jan. 26, 2018 /PRNewswire/ - ESSA Pharma Inc. (TSXV: EPI; Nasdaq: EPIX) ("ESSA" or the "Company") today announced that David R. Parkinson, ...
January 25, 2018
Advaxis’ Immunotherapy in Combination with Chemoradiation Highlighted as Potential Treatment for Anal Cancer in International Journal of Radiation Oncology
PRINCETON, N.J.--(BUSINESS WIRE)--Advaxis, Inc. (ADXS), a late-stage biotechnology company focused on the discovery, development and commercialization of immunotherapy products, today announces that data from the investigator-initiated ...
January 25, 2018
Albireo Prices $65.0 Million Public Offering of Common Stock
BOSTON, Jan. 25, 2018 (GLOBE NEWSWIRE) -- Albireo Pharma, Inc. (ALBO), a clinical-stage orphan pediatric liver disease company developing novel bile acid modulators, announced today ...
January 25, 2018
OSE Immunotherapeutics Receives Notice of Allowance for New Patent by U.S. Patent and Trademark Office that Further Strengthens Intellectual Property Portfolio Around Tedopi® in Immuno-Oncology Applications
NANTES, France, Jan. 25, 2018 (GLOBE NEWSWIRE) -- OSE Immunotherapeutics(ISIN:FR0012127173) (Mnémo:OSE), today announces that it has received a notice of allowance from the U.S. Patent ...
January 25, 2018
Zealand Pharma hosts Capital Market Day: Accelerating the late stage pipeline
Copenhagen 25 January, 2018 - Zealand Pharma (Zealand) will host a Capital Market Day in New York, starting at 12:30 pm ET (6.30 pm CET), ...
January 23, 2018
BioTime to Present at the Noble Capital Markets 14th Annual Institutional Investor Conference in Fort Lauderdale, January 29, 2018
ALAMEDA, Calif.--(BUSINESS WIRE)--BioTime, Inc. (NYSE American: BTX), a late-stage, clinical biotechnology company developing and commercializing products addressing degenerative diseases, today announced that Russell Skibsted, Chief ...
January 23, 2018
BioCanCell Announces Terms of $25 Million Funding Round
JERUSALEM, Jan. 23, 2018 (GLOBE NEWSWIRE) -- BioCanCell Ltd. (TASE:BICL) (the “Company"), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel ...
January 23, 2018
Altimmune Announces Notice of Allowance on Patent Covering Use of NasoShield in the U.S.
GAITHERSBURG, Md., Jan. 23, 2018 (GLOBE NEWSWIRE) -- Altimmune, Inc. (ALT), a clinical-stage immunotherapeutics company, today announced that it has received a Notice of Allowance ...
January 23, 2018
New clinical evidence support potential for glepaglutide as a once-weekly drug for short bowel syndrome (SBS)
Copenhagen, Denmark, January 23, 2018 - Zealand Pharma ("Zealand") reports that the PK profile of their long-acting GLP-2 analog, glepaglutide, supports once- or twice-weekly dosing ...
January 23, 2018
Zealand Pharma to present Phase 2 results on glepaglutide at the ASPEN 2018 Conference in Las Vegas, U.S.
Copenhagen, January 23, 2018 - Zealand Pharma (Zealand) and Rahim M. Naimi, MD, Department of Gastroenterology, Rigshospitalet, University of Copenhagen, Denmark, will present Phase 2 key ...
January 22, 2018
BioTime Announces Clinical and Corporate Milestone Targets for 2018
ALAMEDA, Calif.--(BUSINESS WIRE)--BioTime, Inc. (NYSE American: BTX), a late-stage, clinical biotechnology company developing and commercializing products addressing degenerative diseases, today announced its 2018 clinical and ...
January 22, 2018
Rexahn Pharmaceuticals Announces Poster Presentation of RX-3117 Data in Metastatic Pancreatic Patients at the American Society of Clinical Oncology Gastrointestinal Cancers (ASCO GI) 2018 Annual Meeting
ROCKVILLE, Md., Jan. 22, 2018 (GLOBE NEWSWIRE) --  Rexahn Pharmaceuticals, Inc. (NYSE American:RNN), a clinical stage biopharmaceutical company developing innovative, targeted therapeutics for the treatment ...
January 22, 2018
Altimmune to Participate at the Noble Capital 14th Annual Investor Conference
GAITHERSBURG, Md., Jan. 22, 2018 (GLOBE NEWSWIRE) -- Altimmune, Inc. (ALT), a clinical-stage immunotherapeutics company, announced today that Bill Enright, President and Chief Executive Officer, ...
Page 69 of 117